276 In the index

Dapagliflozin DAPA

An FDA-approved diabetes drug (Farxiga) that also helps with heart failure and kidney disease by having the kidneys remove extra sugar through urine. Large studies show it lowers blood sugar, causes modest weight loss, and meaningfully protects the heart and kidneys, with genital infections being the main downside.

Also known as Farxiga, Forxiga, BMS 512148, dapagliflozine, Dapagliflozina, 1ULL0QJ8UC, CHEBI:85078, DAPAGLIFLOZIN COMPONENT QTERNMET

Effects Longevity Lose fat

Routes Oral

Legal status Prescription drug

WADA Not listed

3D Molecular Structure of C₂₁H₂₅ClO₆

Drag to rotate · scroll to zoom

Chemistry

Formula: C21H25ClO6
Molar mass: 408.9
CAS: 461432-26-8
PubChem CID: 9887712
IUPAC name: (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
InChIKey: JVHXJTBJCFBINQ-ADAARDCZSA-N

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 10 mg

Reported range 5-10 mg/day

Route Oral

Frequency Once daily

Duration Chronic/ongoing (as prescribed)

FDA-approved SGLT2 inhibitor (Farxiga) for type 2 diabetes, heart failure, and chronic kidney disease.

Where this comes from FDA prescribing information

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.